Hypertension, a long-term condition affecting nearly half of adults in the U.S., poses serious health risks like heart attacks, strokes, kidney failure, and dementia. A new treatment called renal denervation is gaining attention as a possible solution for people whose high blood pressure cannot be controlled with medication. Approved by the FDA in late 2023, this minimally invasive procedure targets overactive renal nerves, which are key in regulating blood pressure. Clinical trials show it lowers systolic blood pressure by an average of 8 to 10 points, with some patients seeing greater improvements. However, it’s not suitable for everyone, including those with kidney disease or narrowed arteries.

Renal denervation involves threading a catheter to the kidneys, where ultrasound or radiofrequency energy is used to disable specific nerve pathways. The procedure takes about an hour and is currently available at select hospitals, such as Massachusetts General Brigham. Experts are working to refine eligibility guidelines and ensure insurance coverage, as the procedure costs several thousand dollars. While it offers hope, it does not work for everyone, and long-term effects are still being studied. The American Heart Association advises patients and doctors to weigh the potential benefits and risks. Combined with lifestyle changes and medication, renal denervation may help those struggling with treatment-resistant hypertension.